32

BrainStorm

January 17, 2023

George Vradenburg and the Future of Alzheimer's Advocacy - Part 1

George Vradenburg and the Future of Alzheimer's Advocacy - Part 1

About This Episode

The Food and Drug Administration expedited approval of Lecanemab, a drug developed by Eisai and Biogen, that demonstrated positive results in slowing Alzheimer's disease. What does this mean for the future of Alzheimer’s advocacy?

In this episode of BrainStorm, host Meryl Comer talks with George Vradenburg, Chairman and Co-Founder of UsAgainstAlzheimer’s, Convener of Global CEOi and Co-Convener with the World Economic Forum of the Davos Alzheimer’s Collaborative.  They discuss the immediate implications of the drug approval, how it will impact the Alzheimer’s movement, and what it means for the future of Alzheimer’s disease. 

Do you have feedback or an idea for the podcast? Send us a note at [email protected].
 

Support the show

BrainStorm Feed

105
March 17, 2026 | 26:17

When Memory Fades - Rethinking Alzheimer's from Diagnosis to Care

Host Meryl Comer continues her conversation with Dr. Jason Karlawish, professor of medicine, medical ethics, and neurology at the University of Pennsylvania, about the evolving

LISTEN NOW
104
March 3, 2026 | 27:17

Promoted and Caregiving - The Reality Young Professionals Don't Talk About

What happens when your carefully mapped career path collides with an Alzheimer's diagnosis — and you're only 26? In this deeply personal episode of BrainStorm

LISTEN NOW
103
February 17, 2026 | 23:13

Chipping Away at the Crisis - A New Era in Alzheimer's Diagnosis and Treatment with Dr. Jason Karlawish

Alzheimer's disease is no longer just a memory problem — it's a biological, cultural, and ethical challenge reshaping how we think about aging, identity, and

LISTEN NOW